|
Dr. William A. Scott has extensive research and management experience in both biotechnology and large pharmaceutical companies. Bill was previously Chief Executive Officer of Physiome Sciences, Inc., a company whose mission is to help pharmaceutical companies develop better drugs faster through the use of biological simulations. Prior to that, he held various senior level positions at Bristol-Myers Squibb (BMS) including Senior Vice President, Exploratory and Drug Discovery Research at BMS Pharmaceutical Research Institute from 1990 through 1996. During this period, he oversaw the submission of over 70 new chemical entities for development as new therapeutic agents. He consults or serves as a member of the board of directors of several biotechnology companies, including serving on the boards of publicly-traded AtheroGenics, Inc., Deltagen, Inc. and Variagenics, Inc. Bill holds a B.S. in Chemistry from University of Illinois and a Ph.D. in Biochemistry from the California Institute of Technology. He is also an Adjunct Professor at the Rockefeller University, where he has been affiliated since 1969. | 